A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effect of the Combination of Umeclidinium and Vilanterol on Exercise Endurance Time in Subjects With COPD

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effect of the Combination of Umeclidinium and Vilanterol on Exercise Endurance Time in Subjects With COPD

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Umeclidinium/vilanterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 16 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 19 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 19 Nov 2015 Planned End Date changed from 1 Jan 2016 to 1 May 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top